GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Cash Ratio

SomaLogic (SomaLogic) Cash Ratio : 16.34 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. SomaLogic's Cash Ratio for the quarter that ended in Sep. 2023 was 16.34.

SomaLogic has a Cash Ratio of 16.34. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for SomaLogic's Cash Ratio or its related term are showing as below:

SLGC' s Cash Ratio Range Over the Past 10 Years
Min: 11.51   Med: 15.7   Max: 30.87
Current: 16.34

During the past 3 years, SomaLogic's highest Cash Ratio was 30.87. The lowest was 11.51. And the median was 15.70.

SLGC's Cash Ratio is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.51 vs SLGC: 16.34

SomaLogic Cash Ratio Historical Data

The historical data trend for SomaLogic's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Cash Ratio Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
Cash Ratio
11.51 22.46 12.45

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.27 12.45 12.88 15.05 16.34

Competitive Comparison of SomaLogic's Cash Ratio

For the Health Information Services subindustry, SomaLogic's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomaLogic's Cash Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's Cash Ratio distribution charts can be found below:

* The bar in red indicates where SomaLogic's Cash Ratio falls into.



SomaLogic Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

SomaLogic's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=539.588/43.332
=12.45

SomaLogic's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash Ratio (Q: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=453.81/27.781
=16.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomaLogic  (NAS:SLGC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


SomaLogic Cash Ratio Related Terms

Thank you for viewing the detailed overview of SomaLogic's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director